Loading...
XNASACHV
Market cap106mUSD
Jan 17, Last price  
3.09USD
1D
0.65%
1Q
-39.17%
Jan 2017
-94.38%
Name

Achieve Life Sciences Inc

Chart & Performance

D1W1MN
XNAS:ACHV chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
157.39%
Rev. gr., 5y
%
Revenues
0k
264,962,0008,254,48322,391,85820,130,66320,131,00025,539,00013,616,0005,496,00020,095,00029,882,00027,116,00018,160,0005,062,0000000000
Net income
-30m
L-28.80%
-16,310,592-21,097,017-23,551,296-13,063,168-4,204,0005,476,000-12,584,000-14,673,000-21,098,000-31,849,000-26,240,000-16,801,000-20,129,000-10,583,000-12,687,000-16,141,000-14,661,000-32,902,000-41,875,000-29,815,000
CFO
-24m
L-34.81%
-14,620,625-8,359,213-19,680,553-23,335,332-12,307,00034,878,000-26,840,000-20,263,000-43,493,000-35,927,000-17,308,000-9,101,000-29,683,000-9,107,000-10,623,000-15,216,000-13,474,000-29,440,000-37,549,000-24,479,000
Earnings
Mar 26, 2025

Profile

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
URL
http://achievelifesciences.com/
IPO date
Oct 12, 1995
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
27,478
41,036
Unusual Expense (Income)
NOPBT
(27,478)
(41,036)
NOPBT Margin
Operating Taxes
(475)
Tax Rate
NOPAT
(27,478)
(40,561)
Net income
(29,815)
-28.80%
(41,875)
27.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,271
19,212
BB yield
-18.69%
-74.03%
Debt
Debt current
16,725
58
Long-term debt
75
16,267
Deferred revenue
Other long-term liabilities
Net debt
1,204
(8,496)
Cash flow
Cash from operating activities
(24,479)
(37,549)
CAPEX
(21)
Cash from investing activities
(21)
Cash from financing activities
15,278
19,295
FCF
(27,434)
(40,605)
Balance
Cash
15,546
24,771
Long term investments
50
50
Excess cash
15,596
24,821
Stockholders' equity
(165,657)
(135,845)
Invested Capital
180,940
160,346
ROIC
ROCE
EV
Common stock shares outstanding
19,827
10,593
Price
4.12
68.16%
2.45
-68.51%
Market cap
81,689
214.76%
25,953
-58.92%
EV
82,893
17,457
EBITDA
(27,250)
(40,800)
EV/EBITDA
Interest
2,853
1,789
Interest/NOPBT